About Riverside Partners

• Founded: 1974

• Headquarters: Boston, Massachusetts

• AUM: $6bn as of 2023

• Strategy: Lower middle-market buyout, healthcare and business services

• Track record: Over 300 platform investments across 50 years, typical equity checks $25m–$100m

• Leadership: Stewart Ogilvie and Benet O'Reilly, managing partners

Riverside Partners has rebranded to RS2 Healthcare Partners and closed a continuation vehicle for Loftware, a 2014 healthcare investment. The source does not disclose the CV size or whether existing LPs rolled into the vehicle. The rebrand signals a strategic narrowing to healthcare-focused investing after five decades as a generalist lower middle-market firm.

The timing is notable. Riverside held Loftware for over a decade — well past the typical 5–7 year hold period for middle-market buyouts. CVs have become the mechanism of choice for GPs extending hold periods on assets still generating operational improvement or multiple expansion, particularly in healthcare where consolidation plays can take 8–12 years to mature. A recent comparable: in March 2024, Pharos Capital closed a $340m CV for a 2015 healthcare IT investment, also a decade-old hold.

The rebrand raises a question: whether Riverside is splitting healthcare assets into RS2 while maintaining the Riverside brand for other sectors, or if this represents a full pivot. Healthcare-focused secondaries volume grew 18% year-over-year in 2024, driven by LP demand for exposure to defensive sectors and GP willingness to extend holds in regulatory-sensitive businesses. If RS2 is positioning as a pure-play healthcare sponsor, the CV close and rebrand package together as a credibility signal to LPs in a crowded market.

Source: AltAssets